overall

Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…

1 month ago

XRP payment volume surged 1,300% in a single day, and the XRP Mining platform attracted thousands of investors in a single day

Houston, TX, June 13, 2025 (GLOBE NEWSWIRE) -- Against the backdrop of overall volatility in the crypto market, the XRP…

1 month ago

Dupixent (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall…

2 months ago

Bin There Dump That Named to Entrepreneur Magazines Franchise 500 Hall of Fame

WILMINGTON, Del.--(BUSINESS WIRE)--Bin There Dump That, North America’s leading residential-friendly dumpster rental franchise, has been named to Entrepreneur Magazine’s 2025…

2 months ago

Persistent Achieves Top Rankings for the Second Year in a Row in Extel’s Asia Executive Team Survey

Recognized under multiple categories, including Best CEO, Company Board of Directors, Overall ESG, Best Investor Relations Program, and Best Investor…

2 months ago

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1…

2 months ago

New data show Roches Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced…

2 months ago

Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde regimen in metastatic pancreatic adenocarcinoma

Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic…

2 months ago

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement…

2 months ago